| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10786482 | AZURITY | Enalapril formulations |
Mar, 2036
(11 years from now) | |
| US11040023 | AZURITY | Enalapril formulations |
Mar, 2036
(11 years from now) | |
| US10039745 | AZURITY | Enalapril formulations |
Mar, 2036
(11 years from now) | |
| US9808442 | AZURITY | Enalapril formulations |
Mar, 2036
(11 years from now) | |
| US10154987 | AZURITY | Enalapril formulations |
Mar, 2036
(11 years from now) | |
| US9669008 | AZURITY | Enalapril formulations |
Mar, 2036
(11 years from now) | |
| US10772868 | AZURITY | Enalapril formulations |
Mar, 2036
(11 years from now) | |
| US11141405 | AZURITY | Enalapril formulations |
Mar, 2036
(11 years from now) | |
| US11173141 | AZURITY | Enalapril formulations |
Mar, 2036
(11 years from now) | |
Epaned is owned by Azurity.
Epaned contains Enalapril Maleate.
Epaned has a total of 9 drug patents out of which 0 drug patents have expired.
Epaned was authorised for market use on 20 September, 2016.
Epaned is available in solution;oral dosage forms.
Epaned can be used as treatment of hypertension, treatment of heart failure.
The generics of Epaned are possible to be released after 25 March, 2036.
Drugs and Companies using ENALAPRIL MALEATE ingredient
Market Authorisation Date: 20 September, 2016
Treatment: Treatment of hypertension; Treatment of heart failure
Dosage: SOLUTION;ORAL
EPANED family patents
